从诺和诺德(Novo Nordisk)获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%;净利润

智通财经
Aug 07
从诺和诺德(Novo Nordisk)获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%;净利润达到555.37亿丹麦克朗。明星产品中司美格鲁肽上半年销售额达1127.56亿丹麦克朗。这之中降糖版司美格鲁肽注射液(英文商品名:Ozempic下同)销售额为645.2亿丹麦克朗减重版司美格鲁肽注射液(Wegovy)销售额为368.88亿丹麦克朗。换算成美元便是司美格鲁肽在今年上半年的销售额达到了175亿美元。这也意味着司美格鲁肽的销售成绩于期内超越了药王帕博利珠单抗也就是俗称的“K药”。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10